计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| P612716-1mg |
1mg |
现货 ![]() |
| |
| P612716-5mg |
5mg |
现货 ![]() |
| |
| P612716-10mg |
10mg |
现货 ![]() |
|
| 别名 | 替西替布 |
|---|---|
| 英文别名 | PETESICATIB [WHO-DD] | EX-A3136 | DB15297 | (2S,4R)-N-(1-cyanocyclopropyl)-4-[4-(1-methylpyrazol-4-yl)-2-(trifluoromethyl)phenyl]sulfonyl-1-[1-(trifluoromethyl)cyclopropanecarbonyl]pyrrolidine-2-carboxamide | HY-109069 | SCHEMBL700776 | 1252637-35-6 | A26 |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | petesicatib |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 胰蛋白酶 S 抑制剂 |
| 产品介绍 |
Petesicatib (RO5459072; RG-7625) 是一种 cathepsin S 抑制剂,可用于免疫疾病研究。
Petesicatib (RO5459072; RG-7625) is a cathepsin S inhibitor, used in research of immune diseases.
|
| 纯度 | ≥98% |
| ALogP | 2.6 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | (2S,4R)-N-(1-cyanocyclopropyl)-4-[4-(1-methylpyrazol-4-yl)-2-(trifluoromethyl)phenyl]sulfonyl-1-[1-(trifluoromethyl)cyclopropanecarbonyl]pyrrolidine-2-carboxamide |
| INCHI | 1S/C25H23F6N5O4S/c1-35-11-15(10-33-35)14-2-3-19(17(8-14)24(26,27)28)41(39,40)16-9-18(20(37)34-22(13-32)4-5-22)36(12-16)21(38)23(6-7-23)25(29,30)31/h2-3,8,10-11,16,18H,4-7,9,12H2,1H3,(H,34,37)/t16-,18+/m1/s1 |
| InChi Key | KXAAIORSMACJSI-AEFFLSMTSA-N |
| Smiles | CN1C=C(C=N1)C2=CC(=C(C=C2)S(=O)(=O)[C@@H]3C[C@H](N(C3)C(=O)C4(CC4)C(F)(F)F)C(=O)NC5(CC5)C#N)C(F)(F)F |
| Isomeric SMILES | CN1C=C(C=N1)C2=CC(=C(C=C2)S(=O)(=O)[C@@H]3C[C@H](N(C3)C(=O)C4(CC4)C(F)(F)F)C(=O)NC5(CC5)C#N)C(F)(F)F |
| PubChem CID | 59543597 |
| MeSH Entry Terms | (4R)-N-(1-Cyanocyclopropyl)-4-((4-(1-methyl-1H-pyrazol-4-yl)-2-(trifluoromethyl)phenyl)sulfonyl)-1-((1-(trifluoromethyl)cyclopropyl)carbonyl)-L-prolinamide;2-Pyrrolidinecarboxamide, N-(1-cyanocyclopropyl)-4-((4-(1-methyl-1H-pyrazol-4-yl)-2-(trifluoromethy |
| 分子量 | 603.54 |
| 溶解性 | DMSO: 125 mg/mL (207.11 mM), Sonification is recommended. |
|---|---|
| 分子量 | 603.500 g/mol |
| XLogP3 | 2.600 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 12 |
| 可旋转键计数Rotatable Bond Count | 6 |
| 精确质量Exact Mass | 603.137 Da |
| 单同位素质量Monoisotopic Mass | 603.137 Da |
| 拓扑极表面积Topological Polar Surface Area | 134.000 Ų |
| 重原子数Heavy Atom Count | 41 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 1230.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 2 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Tato M, Kumar SV, Liu Y, Mulay SR, Moll S, Popper B, Eberhard JN, Thomasova D, Rufer AC, Gruner S et al.. (2017) Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury.. Sci Rep, 7 (1): (2775). [PMID:28584258] |
| 2. Theron M, Bentley D, Nagel S, Manchester M, Gerg M, Schindler T, Silva A, Ecabert B, Teixeira P, Perret C et al.. (2017) Pharmacodynamic Monitoring of RO5459072, a Small Molecule Inhibitor of Cathepsin S.. Front Immunol, 8 (806). [PMID:28769925] |